Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Schofield

Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs.  As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Advertisement
Set Alert for Articles By Ian Schofield

Latest From Ian Schofield

French Launch Fast-Track Clinical Trial Approval Scheme

Sponsors are being invited to trial a new fast-track system for authorizing clinical trials as part of French preparations for the new EU trial rules that are set to come into force in 2020.

Clinical Trials France

Health Must Be At Center Of Post-Brexit Relationship, Say Industry & NHS Bodies

UK industry and National Health Service bodies say that the “political declaration” on the future UK-EU relationship fails to address key public health issues such as regulatory cooperation, collaboration in science and innovation, and tackling counterfeit medicines.
Brexit Regulation

UK Court Ruling A Blow For Pfizer And A Warning For Patentees

A UK Supreme Court decision to invalidate Pfizer's pregabalin patent is not only bad news for Pfizer and good news for the generics firms involved – it could also mean that companies have to produce more evidence to substantiate their patent claims in future.
Intellectual Property Regulation

UK Pharma Takes Hope From Draft Brexit Deal But Uncertainty Reigns

The Brexit deal agreed by UK ministers brings little certainty for the life sciences sector.  Moreover, the related and unprecedented political instability means that its final approval is far from guaranteed. 
Brexit Legislation

Brexit: EU Countries Dragging Feet On At-Risk Medicines

The EU regulatory network is finding it difficult to identify non-centrally authorized medicines that are at risk of Brexit-related shortages, a workshop on medicines availability has heard. 
Brexit Regulation

Merck's View On The Challenges Of Ebola Vaccination In The DRC

With the latest Ebola outbreak threatening to spread across the Democratic Republic of Congo and beyond, efforts are being stepped up to vaccinate the at-risk population and health workers with Merck Sharp & Dohme’s experimental vaccine, V920. MSD’s Mel Kohn spoke to the Pink Sheet about the development of the vaccine, the experience gained from its use to date, and the difficulties involved in getting the vaccine to those who need it.
Vaccines Infectious Diseases
See All
Advertisement
UsernamePublicRestriction

Register